Ebola Vaccines Market – Global Analysis & Forecast, 2019 – 2030

Report ID : 221  |  Region : Global

Ebola virus disease (EVD) is also known as Ebola haemorrhagic fever a rare but severe, often fatal illness in humans. The average Ebola virus disease (EVD) case fatality rate is around 50%, but in recent outbreaks, the case fatality rates have varied from 25% to 90%. Unpredictable and sporadic outbreak of Ebola virus remains as a major concern. The increasing concern is owing to its human-to-human transmission which is through direct contact with the blood or body fluids, objects (such as clothes, bedding, needles, and medical equipment), and infected fruit bats or nonhuman primates.

Continuous evaluation of new vaccine candidates is prioritized to address deficiencies of first generation Ebola vaccines. The companies have collaborated with multiple stakeholders and received external funding for development of Ebola virus vaccine. There are various Ebola vaccine candidates in different stages of development. For instance, Novavax’s Ebola vaccine candidate, Ebola GP Vaccine is under Phase 1 clinical trial. It is developed by using the Makona Ebola virus (EBOV) strain which is associated with a high fatality rate of between 50% and 90%.

The other key players involved in development of Ebola vaccine candidates are Bavarian Nordic, Profectus BioSciences, Inc. and GlaxoSmithKline plc. among others.

To gather deep-rooted insights with respect to market dynamics, competitive landscape and to unlock the market potential of Ebola vaccines manufacturing, subscribe to the report by clicking and filling up the ‘Pre-book’ section.